Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study

References

• van Domburg RT, Lemos PA, Takkenberg JJ, van Domburg RT, Lemos PA, Takkenberg JJ, et al. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease. Eur Heart J. 2005; 26: 675–81
   PubMed Web of Science ®Google Scholar
• Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: Part I. Circulation 2003; 107: 2274–9
   PubMed Web of Science ®Google Scholar
• Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: Part II. Circulation 2003; 107: 2383–9
   PubMed Web of Science ®Google Scholar
• O'Neill WW, Leon MB. Drug-eluting stents. Costs versus clinical benefit. Circulation 2003; 107: 3008–11
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788–794
   PubMed Web of Science ®Google Scholar
• Serruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb J, et al. TAXUS II Study Group. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004; 109: 627–33
   PubMed Web of Science ®Google Scholar
• Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559–64
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis S, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A Polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis S, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS Stent. The TAXUS-IV trial. Circulation. 2004; 109: 1942–7
   PubMed Web of Science ®Google Scholar
• Finn AV, Gold HK. One year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. Circulation 2004; 110: e318–9
   Google Scholar
• Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, et al. for the Intracoronary Stenting and Antithrombotic Regimen: Is abciximab a superior way to eliminate elevated thrombotic risk in diabetics (ISAR-SWEET) study investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627–35
   PubMed Web of Science ®Google Scholar
• Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. Ann Intern Med. 1991; 115: 256–65
   PubMed Web of Science ®Google Scholar
• Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. for the ISAR-DIABETES study investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005; 353: 663–70
   PubMed Web of Science ®Google Scholar
• Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. the multivessel angioplasty prognosis study group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990; 82: 1193–202
   PubMed Web of Science ®Google Scholar
• King SB, Mahmud E. Will blocking the platelet save the diabetic?. Circulation 1999; 100: 2466–8
   PubMedGoogle Scholar
• Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists. The diabetic patient. Rev Cardiovasc Med. 2002; 3: S20–7
   Google Scholar
• Lincoff AM. Important triad in cardiovascular medicine. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 2003; 107: 1556–9
   PubMedGoogle Scholar
• Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal ML, Godfrey NK, Coller BS, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients untergoing percutaneous coronary intervention. Circulation 1999;100:1977–82.
   PubMed Web of Science ®Google Scholar
• Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol. 2005; 95: 1–7
   PubMedGoogle Scholar
• Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000; 35: 922–8
   PubMed Web of Science ®Google Scholar
• De Luca L, De Persio G, Minati M, Iacoboni C, Fedele F. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting. Am Heart J. 2005; 149: e11–8
   Google Scholar
• Teirstein PS, Kao J, Watkins M, Tannenbaum MA, Laufer N, Chang M, et al. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol. 2005; 96: 500–5
   PubMedGoogle Scholar
• The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999;100:799–806.
   PubMed Web of Science ®Google Scholar
• Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schomig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92–3
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004; 350: 232–8
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163–7
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ. Inflammation as a therapeutic target: a unique role for abciximab. Am Heart J. 2003; 146: S1–4
   PubMedGoogle Scholar
• Tang WWH, Lincoff AM. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade. The triad revisited. Circulation 2004; 110: 3618–20
   PubMedGoogle Scholar
• Finn AV, Palacios IF, Kastrati A, Gold HK. Drug-eluting stents for diabetes mellitus. A rush to judgment?. J Am Coll Cardiol. 2005; 45: 479–83
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–80
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus eluting stents versus standard stents in patients with stenosis in native coronary artery. N Engl J Med. 2003; 349: 1315–23
   PubMed Web of Science ®Google Scholar
• Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx (ωelocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109: 2273–8
   PubMed Web of Science ®Google Scholar
• Smith SC, Jr, Feldman TE, Hirshfeld, JW, Jr, Jacobs AK, Kern MJ, King SB, 3rd, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166–286.
   PubMedGoogle Scholar